| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
ABSTRACT |
|---|
|
|
|---|
The low affinity receptor for IgE (CD23) is reported to regulate immune and inflammatory events
and as a result, it may have a role in the development of allergic airway inflammation and hyperresponsiveness (AHR). To test this hypothesis CD23-deficient mice were studied following different
modes of allergic sensitization. Mice were actively sensitized either intraperitoneally with ovalbumin (OA)/alum or via the airways (10 days exposure to OA aerosol with no adjuvant). Passive sensitization was performed by intravenous injections of OA-specific IgE. Airway responsiveness, serum IgE and IgG levels were assessed together with airway inflammation. Passive sensitization followed by
airway challenges resulted in increased OA-specific IgG and IgE in the serum of wild-type mice only,
while both the CD23+/+ and CD23
/
groups developed tracheal smooth muscle hyperresponsiveness to electrical field stimulation, indicating that IgE/CD23-mediated immune functions may not be
necessary for the development of allergic changes. Active sensitization of both CD23
/
and CD23+/+
mice resulted in increased serum levels of OA-specific IgE and IgG, airway eosinophilia and significant
AHR when compared with nonsensitized mice. The genetic deficiency of CD23
/
mice not only
failed to prevent but was associated with a significant increase of these responses. These results indicate that CD23 may not be essential for the development of allergen-induced AHR and further, that
its presence may have some inhibitory effects on the allergic response.
| |
INTRODUCTION |
|---|
|
|
|---|
In allergic asthma, a close relationship has been demonstrated
between IgE levels and the degree of AHR (1). Expression of
IgE is thought to be controlled by both heavy-chain switching and the selection of IgE-committed cells. Some of the regulatory circuits for this process are mediated through the low affinity IgE receptor (CD23) either by stimulating B cells to
produce more IgE or, when bound to IgE, by blocking its production (2). CD23 (Fc
RII) is a type II membrane glycoprotein expressed on various cell types, including mature B cells,
follicular dendritic cells, 
T cells, subsets of CD4+ and CD8+
T-cells after activation and eosinophils (3). In addition to regulating IL-4-induced IgE production, CD23 has been implicated in cellular adhesion (4), antigen presentation (5), growth and
differentiation of B and T cells (7), and rescue from apoptosis (9). The expression of CD23 is strikingly increased in allergic disorders (3, 10). Although it is possible that CD23 has an
important role in IgE-mediated priming and activation of cells expressing this receptor, the relationship of CD23 expression to disease and the specific functions of CD23-positive cells is still unclear. Overproduction of IgE in response to common
environmental antigens may be responsible for amplifying immune reactions which in turn lead to sustained inflammation
and airway hyperresponsiveness (AHR). However, the in vivo
relevance of many of these observations has recently been
questioned by a series of studies on gene-targeted mice lacking expression of CD23, since these mice showed no other phenotypic difference, they had normal T and B cell development and demonstrated an increased production of IgE upon parasite infection (11).
While IgE appears to be involved in a network of immune and inflammatory events relating to immediate hypersensitivity reaction, the role of IgE in allergic inflammation is not clear. Using different approaches to sensitization and challenge, which show differences in IgE dependency for development of AHR, we investigated whether CD23 is functionally important to the inflammatory changes which develop following allergic sensitization leading to AHR. In studying IgE dependency for the development of AHR, we demonstrated that 10-day exposure to ovalbumin (OA) exclusively via the airways triggers an IgE-dependent development of tracheal smooth muscle hyperresponsiveness to electrical field stimulation (12, 13). We also utilized passive sensitization where the inflammatory changes induced following limited allergen challenges are mediated exclusively by OA-specific IgE (14). In contrast to 10-day OA exposure or passive sensitization, after systemic sensitization and repeated airway challenge the development of AHR has been shown to be IgE-independent (15), although these mice produce high levels of IgE. These alternative approaches to sensitization and challenge indicated that CD23 may not be essential for the development of allergen-induced AHR.
| |
METHODS |
|---|
|
|
|---|
Mice
CD23 deficient (CD23
/
) and wild type (CD23+/+) mice were generated as previously described (5). The gene-targeted 129/Ola strain was
crossed with C57 Bl/6, then the CD23 deficient F1 heterozygous mice
were backcrossed to C57 Bl/6 mice twice. Those heterozygous mice
were then intercrossed to produce homozygous wild-type and CD23
deficient mice. Confirmation for the functional disruption of the CD23
gene was performed by Southern Blot and Northern Blot analysis and
has been published in detail in an earlier report (10). Briefly, genomic
DNA was prepared from ES cells and adult tail tips. To ascertain targeting of the CD23 allele, 15 µg of DNA was digested with Sph I or
Aat I and probed with a 0.4-kb BstEII/Xba I or a 0.6-kb BamHI/Xba I
genomic DNA fragment. Incorporation of the single neomycin-resistance gene was further confirmed using a neo probe. For analysis of
CD23 mRNA, total RNA was prepared from splenic B cells stimulated with LPS (10 µg/ml) in the presence of IL-4 (60 U/ml, Genzyme)
for 36 h, electrophoresed, transferred to Hybond-N (Amersham) and
hybridized with a CD23 cDNA fragment or a
-actin probe. For analysis of CD23 expression we have performed FACScan analysis. The
antibody used for identifying CD23 was a rat monoclonal antibody
(B3B4) kindly provided by Dr. D. H. Conrad (Virginia Commonwealth University, Richmond, VA) (16). A detailed FACScan analysis of splenocytes and thymocytes as well as immunohistochemical analysis of germinal centers of spleen sections from homozygous CD23 deficient and wild-type mice were published by Fujiwara and coworkers (5).
Mice were housed in pathogen-free conditions and were maintained on an ovalbumin (OA)-free diet. Experiments were performed on age- and sex-matched groups between the age of 8-12 wk.
All experimental animals used in this study were under a protocol approved by the Institutional Animal Care and Use Committee of the National Jewish Medical and Research Center.
Sensitization and Airway Challenge
Mice were exposed to OA following three different protocols: (1) Mice were exposed for 10 consecutive days to an aerosol containing 1% OA using a DeVilbiss Aerosonic 5000 nebulizer (DeVilbiss Health Care Inc., Somerset, PA) as previously described (12); (2) Mice were actively immunized by intraperitoneal injection of 20 µg OA (Grade V; Sigma Chemical Co., St. Louis, MO) together with 20 mg alum (Inject Alum; Pierce, Rockford, IL) in 100 µl PBS (phosphate-buffered saline), or with PBS alone on Day 1 and Day 14. On Days 24, 25 and 26 mice received an aerosol challenge for 20 min with a 1% OA/PBS solution; (3) Mice were passively sensitized with OA-specific IgE as previously described (14). Briefly, mice were injected intravenously with 100 µl of hybridoma supernatant containing 200 µg of OA-specific IgE antibody on three consecutive days (Days 1, 2, 3) prior to four aerosol challenges with 1% OA on Days 5, 6, 7 and 8. As a control, mice received TNP-specific IgE (ATCC, Rockville, MD).
All mice were killed 48 h after their last OA exposure.
Electrical Field Stimulation of Trachea In Vitro
Airway responsiveness to electric field stimulation was determined 48 h
after the last aerosol challenge of mice as described previously (12).
Briefly, tracheas were removed and 0.5 cm long preparations were
placed in Krebs-Henseleit solution suspended by triangular supports
transducing the force of contractions. Electrical field stimulation with
an increasing frequency from 0.5
40 Hz was applied and the contractions measured. Frequencies resulting in 50% of the maximal contractions (ES50) were calculated from linear plots for each individual animal and were compared between the different groups.
In Vivo Measurement of Bronchial Responsiveness to Methacholine (MCh)
Bronchial responsiveness was assessed as a change in airway function after challenge with aerosolized MCh via the airways using a modification of methods previously described in rats (17) and in mice (12, 19). Mice were anesthetized with an intraperitoneal injection of pentobarbital sodium (70 to 90 mg/kg). A stainless steel 18 G tube was inserted as a tracheostomy cannula and was passed through a hole in the Plexiglass chamber containing the mouse. A four-way connector was attached to the tracheostomy tube, with two ports connected to the inspiratory and expiratory sides of a ventilator (Model 683; Harvard Apparatus, South Natwick, MA). Ventilation was achieved at 160 breaths per minute and a tidal volume of 0.15 ml with a positive end-expiratory pressure of 2-4 cm H2O. The Plexiglass chamber was continuous with a 1.0-liter glass bottle filled with copper gauze to stabilize the volume signal for thermal drift.
Transrespiratory pressure was detected by a pressure transducer. Changes in lung volume were measured by detecting pressure changes in the plethysmographic chamber. Flow was measured by digital differentiation of the volume signal. Lung resistance (RL) and dynamic compliance Cdyn) were continuously computed by a Macintosh computer software (Labview; National Instruments, Austin, TX) by fitting flow, volume, and pressure to an equation of motion.
The aerosolized bronchoconstrictor agents were administered through a bypass tubing via an ultrasonic nebulizer placed between the expiratory port of the ventilator and the four-way connector. Aerosolized agents were administered for 10 s with a tidal volume of 0.5 ml. After a dose of inhaled PBS was given, the subsequent values of RL were used as baseline. Starting 3 min after saline exposure, increasing concentrations of MCh were given by inhalation (10 breaths), with the initial concentration set at 0.4 mg/ml. Increasing concentrations were given at 5-7 min intervals. Hyperinflations of twice the tidal volume were applied between each MCh concentration and performed by manually blocking the outflow of the ventilator in order to reverse any residual atelectasis and ensure a constant volume history prior to challenge. From twenty seconds up to three minutes after each aerosol challenge, the data of RL and Cdyn were continuously collected and maximum values of RL and minimum values of Cdyn were taken to express changes in murine airway function.
Serum Collection
Venous blood was collected from the tail vein before and at different
time points during the sensitization period into serum separator tubes
(Microtainer; Becton-Dickinson, Franklin Lakes, NJ). Serum samples
were stored at
20° C pending analysis.
ELISA for Immunoglobulins
Serum antibody levels were determined as previously described (12). Briefly, ELISA plates (Dynatech, Chantilly, VA) were coated with OA (20 µg/ml NaHCO3 buffer, pH 9.6) or with polyclonal goat anti-mouse IgE 3 µg/ml (The Binding Site Ltd., San Diego, CA) and incubated overnight at 4° C. Plates were blocked with 0.2% gelatin buffer (pH 8.2) for 2 h at 37° C. Serum was diluted 1:10. Standards containing OA-specific IgE and IgG were generated as described (20). For total immunoglobulins, commercial standards were used (Pharmingen, San Diego, CA). ELISA data were analyzed with the Microplate Manager software program for the Macintosh (Bio-Rad Labs, Richmond, VA).
Mononuclear Cell Culture for Proliferation Assay
Spleens were removed and placed in sterile PBS. Single-cell suspensions were prepared and mononuclear cells were purified by density
gradient centrifugation (Lymphocyte Separation Medium; Organon
Teknika, Durham, NC). Cells were washed, counted and resuspended in culture medium (RPMI 1640; GIBCO BRL, Gaithersburg, MD),
containing heat-inactivated fetal calf serum (FCS 10%; Hyclone, Logan, UT), L-glutamine (2 mM), 2-mercaptoethanol (5 mM), HEPES
buffer (15 mM), penicillin (100 U/ml), and streptomycin (100 µg/ml),
all from GIBCO BRL. Cells were plated at 2 × 106/ml in 96-well
round bottom tissue culture plates in triplicate and incubated with
medium alone, OA (100 ng/ml) or the combination of phorbol 12.13-dibutyrate (10 nM) and ionomycin (0.5 µM) for 48 h in a humidified
atmosphere of 5% CO2 at 37° C. Cell free supernates were harvested
and stored at
20° C pending cytokine ELISA assays. Cell proliferation was assessed by uptake of (3H)-thymidine which was added to
cell culture wells for the last 16 h of the incubation period. After incubation, cells were harvested onto a glass-fiber filter paper using a cell
harvester apparatus and the incorporated radiolabel was counted using a
-spectrometer. Results were expressed as mean counts of triplicate cultures.
BAL and Lung Digest Differential Cell Count
After measurement of lung function parameters, lungs were lavaged with 1 ml aliquots of 0.9% wt/vol. of sterile NaCl (room temperature) through a polyethylene syringe attached to the tracheal cannula. Lavage fluid was centrifuged (500 × g for 10 min at 4° C), and the cell pellet was resuspended in 0.5 ml of RPMI tissue culture medium.
Lung digestion was performed after exsanguination and perfusion of the lungs following the protocol previously described from our laboratory (14). Cells from BAL or lung digests were resuspended in RPMI and counted with a hemocytometer. Differential cell counts were made from cytospin preparations as described (14, 18). Cells were identified as macrophages, eosinophils, neutrophils and lymphocytes by standard morphology and at least 500 cells counted under ×400 magnification. The percentage and absolute numbers of each cell type were calculated.
Immunolabeling of Eosinophils
Immunocytochemistry was performed as described previously (20).
Briefly, lung tissue was removed and fixed in 10% formalin solution.
Four µm thick sections were cut, deparaffinized and treated with porcine trypsin for 30 min, 37° C. After washing 3 times, 10% goat serum
was applied for 30 min at room temperature. Primary antibodies (rabbit
polyclonal anti-mouse MBP, a gift of Dr. G. Gleich, Rochester, MN,
and Dr. J. Lee, Scottsdale, AZ) were diluted in 3% goat serum and
applied at 4° C overnight. Slides were then washed and stained with
1% Chromotrope 2R (Harlesco, Gibbstown, NJ) for 30 min at room
temperature. After washing FITC-conjugated goat anti-rabbit secondary antibody was used and the slides were incubated for 1 h at room
temperature in the dark. Coverslips were applied with Fluoromount.
Slides were kept in
20° C until they were examined by a Zeiss microscope equipped with a fluorescein filter system under ×200 magnification. For counting, a computer software program was used (IP Lab
Spectrum, Signal Analytics Co., Vienna, VA) and results were expressed as number of positive cells/unit area.
Data Analysis
Data were expressed as mean ± SEM. Nonparametric analysis of variance (Kruskal-Wallis method) was used to determine significant variance among the groups. If a significant variance was found, the Mann-Whitney U test was used to analyze the differences between individual groups. In the case of multiple comparisons, the Bonferroni correction was applied. A p value of < 0.05 was considered as significant. Data were analyzed with the MINITAB standard statistical package.
| |
RESULTS |
|---|
|
|
|---|
Kinetics of Immunoglobulin Production in Wild-Type and CD23-Deficient Mice
In mice sensitized (i.p.) and challenged with OA, serum samples were obtained on Days 0, 7, 14, 21, and 28. Immunoglobulin values were presented on a log scale throughout. Total IgG
levels remained relatively constant (approximately 100 ng/ml)
during this time period (Figure 1A). Total IgE levels plateaued at ~ 50 ng by Day 14 to Day 21 in both CD23
/
and
CD23+/+ groups (Figure 1B). There was no OA-specific IgG
present in the samples before sensitization. After the first injection it rapidly increased with an additional increase after
the booster on Day 14, and plateaued on Day 21. CD23+/+ and
CD23
/
mice showed identical changes. OA-specific IgE concentrations in the wild type mice reached a plateau by Day 14 and declined through Day 28 (Figure 2B). In the CD23
/
mice, OA-specific IgE reached significantly higher levels (p < 0.05, n = 12) on Days 14 and 21 when compared with CD23+/+
mice (Figure 2B). Without sensitization, aerosol exposure to OA for 3 consecutive days did not affect serum IgE levels in
either group (data not shown).
|
|
Ten days OA-aerosol exposure also resulted in significant increases in OA-specific IgE levels which were comparable in the two groups of mice (Figure 2B). Mice that received 10 day-PBS exposure had no OA-specific immunoglobulins (data not shown).
Effects of Passive Sensitization with OVA-Specific and TNP-Specific IgE on Immunoglobulin Levels Following Airway Exposure to OA
We determined whether passive sensitization with OA-specific IgE would potentiate antibody responses following OA
exposures of the airways. Mice received 100 µl of hybridoma
supernatant intravenously, containing either OA-specific or
TNP-specific IgE on three consecutive days prior to aerosol
challenge with 1% OA on four consecutive days. Serum samples were collected for immunoglobulin assays 48 h after the
last challenge. Figure 3 illustrates the levels of OA-specific
IgG or IgE in the serum of either CD23+/+ and CD23
/
mice
on a log scale. Four airway challenges with OA alone, failed to
induce OA-specific IgG or IgE production. In passively sensitized mice, OA-specific IgG was found only in the CD23+/+
mice, while the CD23
/
mice had no detectable OA-specific
IgG in their serum (Figure 3A). Mice passively sensitized with
IgE without OA-airway challenge failed to develop IgG or
IgE antibodies. There were significant differences in the IgG
and IgE levels between mice receiving OA-IgE alone and mice
receiving OA-IgE as well as four airway challenges in the
CD23+/+ group but not in the CD23
/
animals. OA-specific
IgE was found in the serum of both CD23+/+ and CD23
/
groups. Following OA-IgE injection and four days OA nebulization, the OA-specific IgE levels in CD23
/
mice were 25 ± 3 ELISA U/ml as opposed to 365 ± 24 ELISA U/ml in the
CD23+/+ mice. This difference is statistically significant (p < 0.01). Values in the control groups were less than 10 ELISA
U/ml (Figure 3B).
|
Proliferative Response of Mononuclear Cells from
Sensitized CD23
/
and CD23+/+ Mice
We compared the capability of lymphocytes from CD23
/
and CD23+/+ mice to proliferate in response to antigen. Mononuclear cell preparations from the spleens of both groups responded with dose-dependent proliferative responses following intraperitoneal sensitization. As indicated in Table 1, there
were no significant differences between the groups. Mononuclear cells from nonsensitized mice did not show any antigen-induced proliferation (data not shown).
|
BAL and Lung Digest Cellular Content in Wild Type and CD23-Deficient Mice
Animals exposed to OA over 10 d demonstrated significant
increases in eosinophil numbers in the lung digests. Although
there was a trend for higher eosinophil counts in CD23
/
mice
it did not reach statistical significance (p = 0.065) (Figure 4).
Following this protocol in this mouse strain we were not able to find significant inflammatory changes in the BAL samples
when compared with control mice receiving 10 d PBS. The
BAL cellular content in these mice was virtually identical to
the control values in both of the CD23
/
and CD23+/+ groups.
|
|
The numbers of total leukocytes and macrophages recovered from BAL of intraperitoneally sensitized mice were significantly higher than in nonsensitized animals, in both the
CD23-deficient and wild-type animals (Figure 5). While there
were no eosinophils and neutrophils in nonsensitized mice, the
sensitized and challenged animals from both of the CD23+/+
and CD23
/
groups demonstrated a marked increase in inflammatory cells, particularly eosinophils. The proportion of
eosinophils reached approximately 63% in the wild-type and
72% in the CD23
/
mice.
The number of eosinophils in the lung digests obtained
both from sensitized and challenged CD23+/+ and CD23
/
mice were significantly elevated when compared with controls. Furthermore, CD23
/
mice had significantly higher eosinophil levels than the wild-type mice (Figure 6).
|
Tissue Eosinophil Influx Following Sensitization and
Challenge of CD23+/+ and CD23
/
Mice
In order to directly examine the level of eosinophilia in the
peribronchial tissue we performed immunolabeling of eosinophil major basic protein (MBP) on formalin fixed, paraffin
embedded tissue sections. The tissue samples were taken 48 h
after the last OA-aerosol challenge. In both CD23
/
and in
CD23+/+ mice we failed to detect any positively stained cells
following three OA nebulizations alone (Figure 7A). However, sensitized mice which received aerosol challenges developed a marked eosinophilia in both groups. The eosinophils
(MBP+ cells) were accumulated in the peribronchial and perivascular submucosal tissue, while the lung parenchyma remained
relatively eosinophil free. A few cells could also be seen penetrating the airway epithelium, traveling through to the lumen
(Figure 7B). We observed the following morphological changes
after sensitization and challenge of mice: (1) thickening of the
submucosal tissue probably due to edematous changes and a
large number of inflammatory cells; (2) the inflammatory cell
infiltrate consisted mainly of eosinophils; (3) lymphoid tissue
proliferation at certain sites. No basement membrane thickening, epithelium disruption or airway hyperplasia was observed
probably due to the acute nature of our model (the mice were
sacrificed 48 h after the last OA challenge). In all of these parameters, we were unable to identify any differences between
CD23+/+ and CD23
/
mice.
|
Tracheal Smooth Muscle Reactivity in
CD23+/+ and CD23
/
Mice
To monitor airway responsiveness in the different groups following all three modes of sensitization/challenge (10 d OA exposure, i.p. OA/alum injections and OA challenges, passive sensitization with IgE and OA challenges), we used electric field stimulation of tracheal preparations. ES50 values from individual dose-response curves were calculated and the ratio (%) relative to naive controls are depicted in Figure 8. A decrease in ES50 represents an increase in responsiveness (13).
|
As shown in Figure 8A, passively sensitized mice which received OA-specific IgE prior to four OA-aerosol challenges
demonstrated significant decreases in ES50 when compared
with mice which were injected with TNP-specific IgE or which
received nebulized OA alone. Further, there were no differences between the CD23+/+ and CD23
/
groups.
Active sensitization of CD23+/+ and CDE23
/
mice following 10 days OA exposure as well as sensitization with OA/
alum and OA aerosol challenges resulted in significant and
comparable decreases in ES50 as illustrated in Figure 8B. Mice
receiving 3 d OA exposure alone, demonstrated no difference
from responsiveness of naive controls. Mice which were i.p.
sensitized but challenged with PBS instead of OA showed no
significant differences from the control animals (data not shown).
Airway Responsiveness to Methacholine in Wild Type and CD23-Deficient Mice
Figure 9 presents the dose-response curves of pulmonary resistance (RL) plotted against concentrations of inhaled MCh
in mice sensitized with OA/alum (or injected with PBS) followed by airway challenges. Nonsensitized but OA-challenged
animals from the CD23
/
and CD23+/+ groups were not significantly different and demonstrated changes in RL in response
to increasing concentrations of MCh, which were similar to
normal C57/B6 mice (data not shown). Sensitization and challenge with OA resulted in significant increases in airway responsiveness. CD23
/
mice were more responsive than the
CD23+/+ mice as demonstrated by a two-way ANOVA test (p <
0.01). In addition, there was a significant difference between
these two groups at 50 mg/ml MCh (p < 0.01) (Figure 9A).
|
PC100 and 200 (provocative concentrations of MCh which
cause 100 and 200% increases in lung resistance above baseline) were calculated by log-linear transformation of the dose-response curves. Each of these PC values was significantly
lower in CD23
/
mice than in their wild-type littermates (Figure 9B).
We have additionally compared the changes of dynamic
compliance (Cdyn) in these mice. This parameter has several
determinants including airway resistance to flow, tissue resistance to deformation and elastic recoil of the lung tissue; thus,
it is useful in detecting changes in the small airways and peripheral tissue. While sensitization and challenge resulted in
significant decreases in the Cdyn values (ANOVA p < 0.01) in
both the CD23+/+ and CD23
/
mice (Figure 9C), there were
no significant differences detectable by Cdyn between CD23+/+
and CD23
/
mice.
| |
DISCUSSION |
|---|
|
|
|---|
CD23 has been widely implicated in the synthesis of IgE as
well as in IgE-mediated immune and inflammatory functions
(2). As a result, CD23 may have a pivotal role in the development and maintenance of allergic inflammation. We tested
this hypothesis in a mouse model of allergic AHR and found
that following sensitization and challenge with OA, neither
production of IgE nor the development of airway inflammation and AHR were inhibited in CD23
/
mice.
We compared the allergic responses in CD23+/+ and
CD23
/
mice using three different sensitization protocols.
First, mice received nebulization with OA for 10 consecutive
days. This approach does not involve adjuvant treatment and
antigen exposure is solely via the airways (12), mimicking natural conditions more closely. Further, the development of
tracheal smooth muscle hyperresponsivness to electrical field
stimulation in this model appears dependent on IgE production and eosinophilic infiltration of the airways (12, 20).
Mice in this study produced moderately elevated OA-specific
IgE levels, some eosinophilic inflammation in the peribronchial regions and tracheal smooth muscle hyperresponsiveness to electrical field stimulation, in both the CD23
/
and CD23+/
groups. These data suggest that CD23 has no profound effect
on the allergic changes in the 10 d OA-exposure model.
In a second protocol, we further amplified the allergic responses in order to be able to study and compare the kinetics of immunoglobulin production in CD23 deficient and wild-type mice, as well as to examine changes in airway inflammation and airways responsiveness to nebulized MCh in vivo. It has previously been shown that high levels of IgE and eosinophilic airway inflammation can be achieved by airway challenges of systemically (i.p.) sensitized animals (17, 21). Following this approach, the mice produced marked increases in OA-specific IgE and IgG, a significant airway inflammatory cell infiltration with predominance of eosinophils, tracheal hyperreactivity to electric field stimulation and increased responsiveness to MCh in vivo, again, in both groups of mice. However, the changes were significantly higher in the CD23-deficient mice suggesting an inhibitory effect of CD23 when high levels of IgE are involved in the allergic response.
Finally, in order to study the importance of CD23/IgE-
mediated events on the development of allergic response independently, we used a third protocol in which CD23+/+ and
CD23
/
mice were passively sensitized with OA-specific IgE
prior to OA challenges. A similar method has previously been
described in our laboratory and was shown to induce tracheal
smooth muscle hyperresponsiveness to electrical field stimulation (14). The role of CD23 in enhancing antigen presentation
by binding antigen-IgE complexes seems to be the most consistent feature among human and murine immune responses.
The absence of upregulation of OA-specific IgG1 and IgE
production in CD23
/
mice following administration of anti-OA IgE supports these observations. However, this mechanism does not seem to play a role in the development of tracheal smooth muscle hyperresponsiveness.
There are a number of studies suggesting that CD23 is involved in increased IgE production presumably by interacting
with its ligand, CD21 on the B cell surface (21). Further, in
vivo anti-CD23 antibody treatment of rats was shown to inhibit specific IgE immune responses (22) supporting a role for
CD23 as an enhancer of IgE production. However, the function of CD23 may be more complex as shown by seemingly
controversial data. Actively sensitized CD23
/
mice in our
studies produced significantly higher amounts of OA-specific
IgE while their OA-specific IgG levels remained the same
when compared with their CD23+/+ littermates. These data suggest that presence of CD23 in this mouse model may exert a
specific inhibitory effect to a certain extent on IgE production,
following systemic (i.p.) sensitization. It has indeed been demonstrated that while a soluble form of CD23 increased the
spontaneous as well as IL-4-induced IgE synthesis by B cells
(23), ligation of the membrane form of CD23 inhibited IgE
production (24). In addition, in humans, most of the regulatory function of soluble CD23 is ascribed to its IgE binding capacity but in mice there is no evidence to support that soluble
CD23 retains IgE binding (25). Other laboratories using CD23-deficient mice have demonstrated that these animals have normal T and B cell development and function with normal or
enhanced IgE production following sensitization to antigen
(5) or parasite infection (26, 27). Further, using heterozygous
(CD23+/
) populations of gene-targeted mice, an inverse relationship was revealed between the expression of CD23 and
levels of IgE produced after parasite infections (26). Taken together, these data suggest that in murine systems, the inhibitory, membrane bound form of CD23 may be the dominating
IgE-regulatory factor.
Antigen-IgE complexes bound to CD23 are described to
facilitate antigen presentation to specific T cells, thereby amplifying T cell responses in vitro (5, 6). We have previously
shown that such in vitro upregulation of T cell function following exogenous IgE treatment could be abolished after addition
of anti-CD23 antibody, and was absent in cells from CD23 deficient mice (28). In vivo studies have also demonstrated an impaired capability of CD23
/
mice to utilize the enhancing effects of antigen-specific IgE treatment in immunoglobulin
production (5). We found that passive sensitization with OA-specific IgE (but not anti-TNP IgE) antibody prior to repeated inhalational exposures to OA, was associated with significantly enhanced immune responses including OA-specific immunoglobulin (IgG and IgE) production in CD23+/+ but
not in CD23
/
mice. These data confirmed that in the absence of CD23, the enhancing effects of IgE on certain immune functions are indeed impaired. Interestingly, following
this sensitization protocol, CD23
/
mice were still perfectly
capable of developing tracheal smooth muscle hyperresponsiveness to electrical field stimulation, indicating that facilitated antigen presentation through IgE-CD23, may be of little
importance in this murine model.
Sensitized and challenged mice developed a marked increase in the number of eosinophils both in the BAL fluid and
in the airway submucosal tissue. In addition, quantitative evaluation of whole lung digests revealed a significant increase in
the eosinophilia of CD23
/
mice when compared to wild-type
littermates. The higher number of eosinophils and the fact
that CD23
/
mice were able to produce significantly larger
amounts of OA-specific IgE may account for their increased
RL response to MCh. Immunocytochemistry of the lung tissue
showed that eosinophils were accumulated in the peribronchial-perivascular area in sensitized and challenged mice while
the parenchyma was relatively eosinophil-free. While the precise mechanism whereby eosinophils affect function is not known, it is suggested that eosinophil granule products increase airway responsiveness to nonspecific stimuli in vivo.
CD23 may play a role in IgE-mediated eosinophil degranulation (29). Our experiments however, did not support this hypothesis since the absence of CD23 did not inhibit MCh-
responsiveness in the CD23
/
mice. Recently, two different
mRNA species were described in humans, CD23a and CD23b
(30). Both forms have been identified on B cells, but only
CD23b was found on other cell types such as T cells, dendritic
cells, platelets and eosinophils (3, 11). The presence of form b
has been confirmed in the mouse, and it is not known whether
eosinophils in this species express CD23.
Although availability of immunologically relevant transgenic or `knockout' mice have proven important for studying
models of allergic sensitization (31), site-specific alterations of the mouse genome can often result in surprising phenotypes
(32). While constructing the mutations carrying loss-of-function or null-alleles of the gene of interest is technically the
simplest, there are a number of limitations to this approach.
These include a redundancy in the genome that allows multiple genes to perform overlapping functions, as well as the ability of the genes to compensate for the absent function of the
targeted gene. Since surface expression of CD23 was completely absent in the homozygous gene-deficient mice in the
present study, the findings of increased functional consequences (such as heightened RL) may be explained by compensatory mechanisms of other membrane structures that are able to bind and mediate functions of IgE in a similar fashion to that of CD23. Several different classes of such IgE-binding molecules have been found (the best known are Fc
RI and
Mac-2). These molecules are structurally unrelated, they are
encoded by different genes and may be detected on the cell
surface, in the cytoplasm and the nucleus of various cell types,
particularly after activation (33). Further studies are needed
to clarify the involvement of these IgE-binding molecules in
IgE-mediated functions and the possible regulatory relationships between them.
In the absence of functionally active CD23 in the CD23
/
mice we observed enhanced allergic responsiveness following
i.p. sensitization and repeated airway challenge. There are at
least two possible explanations: (1) The absence of CD23 may
activate another, functionally similar gene which compensates
or overcompensates for the loss of CD23. Evidence for this is
still missing, although such compensation has been described
following targeting of other genes (32). (2) If ligation of CD23
plays an inhibitory role on IgE production, its absence would
lead to enhanced responses. Our findings on the effects of
anti-CD23 antibody (B3B4) which suppresses IgE production
and inhibits the development of airway inflammation and hyperresponsiveness suggest that binding of CD23 with this antibody results in negative regulatory signals (manuscript in preparation). This is supported by studies on CD23 transgenic mice which demonstrate a severely impaired capability to produce IgE (34).
In conclusion, the present experiments demonstrate that
CD23 deficient mice are not impaired in their ability to produce IgE or to develop allergic airway inflammation and AHR
following active allergic sensitization and challenge. The allergen-induced responses are in fact enhanced in these mice, implying that a negative regulatory effect of CD23 on allergic inflammation may be deficient in the CD23
/
animals.
| |
Footnotes |
|---|
Correspondence and requests for reprints should be addressed to Dr. Erwin W. Gelfand, Department of Pediatrics, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206.
(Received in original form January 27, 1997 and in revised form June 27, 1997).
Acknowledgments: The authors are grateful for the expert help of Diana Nabighian in preparing this manuscript and to Lynn Cunningham in performing the immunolabelling of eosinophils.
This work was supported by grant HL-36577 (E.W.G.) from the National Institutes of Health.
| |
References |
|---|
|
|
|---|
1. Burrows, B., F. Martinez, R. Halonen, R. Barbee, and M. Cline. 1989. Association of asthma with serum IgE levels and skin reactivity to allergens. N. Engl. J. Med. 320: 271-277 [Abstract].
2. Sutton, B. J., and H. J. Gould. 1993. The human IgE network. Nature 366: 421-428 [Medline].
3. Delespesse, G., U. Suter, D. Mossalayi, B. Bettler, M. Sarfati, H. Hofstetter, E. Kilcherr, P. Debre, and A. Dalloul. 1991. Expression, structure and function of the CD23 antigen. Adv. Immunol. 49: 149-191 [Medline].
4. Bonnefoy, J.-Y., S. Pochon, J.-P. Aubry, P. Graber, J.-F. Gauchat, K. Jansen, and L. Flores-Romo. 1993. A new pair of surface molecules involved in IgE regulation. Immunol. Today 14: 1-2 [Medline].
5.
Fujiwara, H.,
H. Kikutani,
S. Suematsu,
T. Naka,
K. Yoshida,
T. Tanaka,
M. Suemura,
N. Matsumoto,
S. Kojima,
T. Kishimoto, and
N. Yoshida.
1994.
The absence of IgE antibody-mediated augmentation of immune responses in CD23 deficient mice.
Proc. Natl. Acad. Sci. U.S.A.
91:
6835-6839
6. Gustavsson, S., S. Hjulstrom, T. Liu, and B. Heyman. 1994. CD23/IgE mediated regulation of the specific antibody response in vivo. J. Immunol. 152: 4793-4800 [Abstract].
7.
Mossalayi, M. D.,
J. C. Lecron,
A. H. Dalloul,
M. Sarfati,
J. M. Bertho,
H. Hofstetter,
G. Delespesse, and
P. Debre.
1990.
Soluble CD23
(FceRII) and interleukin 1 synergistically induced early human thymocyte maturation.
J. Exp. Med.
171:
959-964
8. Gordon, J., J. A. Cairns, M. J. Millsum, S. Gillis, and G. R. Guy. 1988. Interleukin 4 and soluble CD23 as progression factors for human B lymphocytes: analysis of their interactions with agonists of the phosphoinositide "dual pathway" of signaling. Eur. J. Immunol. 18: 1561-1565 [Medline].
9. Bonnefoy, J. Y., S. Henchoz, D. Hardie, M. J. Holder, and J. Gordon. 1993. A subset of anti-CD21 antibodies promotes the rescue of germinal center B cells from apoptosis. Eur. J. Immunol. 23: 969-972 [Medline].
10. Melewicz, F. M., R. S. Zeiger, M. H. Mellon, R. D. O'Connor, and H. L. Spielberg. 1981. Increased peripheral blood monocytes with Fc receptors for IgE in patients with severe allegic disorders. J. Immunol. 126: 1592-1595 [Abstract].
11. Lamers, M. C., and P. Yu. 1995. Regulation of IgE synthesis: lessons from the study of IgE transgenic and CD23-deficient mice. Immunol. Reviews 148: 71-95 [Medline].
12. Larsen, G. L., H. Renz, J. E. Loader, K. L. Bradley, and E. W. Gelfand. 1992. Airway response to electric field stimulation in sensitized inbred mice: passive transfer of increased responsiveness with peribronchial lymph nodes. J. Clin. Invest. 89: 747-752 .
13.
Hamelmann, E.,
A. T. Vella,
A. Oshiba,
J. W. Kappler,
P. Marrack, and
E. W. Gelfand.
1997.
Allergic airway sensitization induced T-cell activation but not airway hyperresponsiveness in B cell deficient mice.
Proc. Natl. Acad. Sci. U.S.A.
94:
1350-1355
14. Oshiba, A., E. Hamelmann, K. Takeda, K. L. Bradley, J. E. Loader, G. L. Larsen, and E. W. Gelfand. 1996. Passive transfer of immediate hypersensitivity and airway hyperresponsiveness by allergen-specific immunoglobulin (Ig) E and IgG1 in mice. J. Clin. Invest. 97: 1398-1408 [Medline].
15. Gelfand, E. W., A. T. Vella, P. Marrack, and E. Hamelmann. 1997. Development of eosinophilic airway inflammation and airway hyperresponsiveness (AHR) in allergen-sensitized B-cell deficient mice. J. Allergy Clin. Immunol. 99: S266 .
16. Rao, M., W. T. Lee, and D. H. Conrad. 1987. Characterization of a monoclonal antibody directed against the murine B lymphocyte receptor for IgE. J. Immunol. 138: 1845-1851 [Abstract].
17. Kips, J. C., C. A. Cuvelier, and R. A. Pauwels. 1992. Effect of acute and chronic antigen inhalation on airway morphology and responsiveness in actively sensitized rats. Am. Rev. Respir. Dis. 145: 1306-1310 [Medline].
18. Haczku, A., K. F. Chung, J. Sun, P. J. Barnes, A. B. Kay, and R. Moqbel. 1995. Airway hyperresponsiveness, elevation of serum specific IgE and activation of T cells following allergen exposure in sensitized Brown-Norway rats. Immunology 85: 598-603 [Medline].
19.
Martin, T. R.,
N. P. Gerard,
S. J. Galli, and
J. M. Drazen.
1988.
Pulmonary responses to bronchoconstrictor agonists in the mouse.
J. Appl.
Physiol.
64:
2318-2323
20. Hamelmann, E., A. Oshiba, J. Loader, G. L. Larsen, G. Gleich, J. Lee, and E. W. Gelfand. 1997. Anti-interleukin 5 (IL-5) antibody prevents airway hyperresponsiveness in a murine model of airway sensitization. Am. J. Respir. Cell Mol. Biol. 16: 674-682 [Abstract].
21. Aubry, J. P., S. Pochon, P. Graber, K. U. Jansen, and J. Y. Bonnefoy. 1992. CD21 is a ligand for CD23 and regulates IgE production. Nature 358: 505-507 [Medline].
22.
Flores Romo, L., J. Shields, Y. Humbert, P. Graber, J. P. Aubry, J. F. Gauchat, G. Ayala, B. Allet, M. Chavez, H. Bazin, M. Capron, and
J. T. Bonnefoy.
1993.
Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23.
Science
261:
1038-1041
23.
Delespesse, G., and
M. Sarfati.
1991.
An update on human CD23
(FceRII), Fc
R-II and IgE-BFs (soluble CD23) play an essential role
in the regulation of human IgE synthesis.
Clin. Exp. Allergy
21S:
153-161
.
24.
Sherr, E.,
E. Macy,
H. Kimata,
M. Gilly, and
A. Saxon.
1989.
Binding the
low affinity Fc
R-II on B cells suppresses ongoing human IgE synthesis.
J. Immunol.
142:
481-489
[Abstract].
25. Lee, W. T., M. Rao, and D. H. Conrad. 1987. The murine lymphocyte receptor for IgE: IV. The mechanism of ligand-specific receptor upregulation on B cells. J. Immunol. 139: 1191-1198 [Abstract].
26. Stief, A., G. Texido, G. Sansig, H. Eibel, G. Le Gros, and H. Van der Putten. 1994. Mice deficient in CD23 reveal its modulatory role in IgE production, but no role in T and B cell development. J. Immunol. 152: 3378-3385 [Abstract].
27. Yu, P., M. Kosco-Vibois, M. Richards, G. Kohler, and M. C. Lamers. 1994. Negative feedback regulation of IgE synthesis by murine CD23. Nature 369: 753-756 [Medline].
28. Oshiba, A., E. Hamelmann, A. Haczku, K. Takeda, D. H. Conrad, H. Kikutani, and E. W. Gelfand. 1997. Modulation of antigen-induced B and T cell responses by antigen-specific IgE antibody. J. Immunol. (In press)
29. Capron, M., M. J. Truong, D. Aldebert, V. Gruart, M. Suemura, G. Delespesse, B. Tourvieille, and A. Capron. 1992. Eosinophil IgE receptor and CD23. Immunol. Res. 11: 252-259 [Medline].
30.
Yokota, A.,
K. Yukawa,
A. Yamamoto,
K. Sugiyama,
M. Suemura,
Y. Tashiro,
T. Kishimoto, and
H. Kikutani.
1992.
Two forms of the low-affinity Fc receptor for IgE differentially mediate endocytosis and
phagocytosis: identification of the critical cytoplasmic domains.
Proc.
Natl. Acad. Sci. U.S.A.
89:
5030-5034
31.
Drazen, J. M.,
J. P. Arm, and
K. F. Austen.
1996.
Sorting out the cytokines of asthma.
J. Exp. Med.
183:
1-5
32. Thomas, K. R.. 1995. The knockout mouse: six years old and growing stronger. Am. J. Respir. Cell Mol. Biol. 12: 461-463 [Medline].
33. Liu, F. T.. 1990. Molecular biology of IgE-binding proteins: IgE-binding factors and IgE receptors. CRC Crit. Rev. Immunol. 10: 289-306 .
34. Texido, G., H. Eibel, G. Le Gros, and H. van der Putten. 1994. Transgene CD23 expression on lymphoid cells modulates IgE and IgG1 responses. J. Immunol. 153: 3028-3042 [Abstract].
This article has been cited by other articles:
![]() |
C. von Garnier, M. E. Wikstrom, G. Zosky, D. J. Turner, P. D. Sly, M. Smith, J. A. Thomas, S. R. Judd, D. H. Strickland, P. G. Holt, et al. Allergic Airways Disease Develops after an Increase in Allergen Capture and Processing in the Airway Mucosa J. Immunol., November 1, 2007; 179(9): 5748 - 5759. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kitamura, K. Takeda, T. Koya, N. Miyahara, T. Kodama, A. Dakhama, T. Takai, A. Hirano, M. Tanimoto, M. Harada, et al. Critical Role of the Fc Receptor {gamma}-Chain on APCs in the Development of Allergen-Induced Airway Hyperresponsiveness and Inflammation J. Immunol., January 1, 2007; 178(1): 480 - 488. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. P. Ennis, J. P. Cassidy, and B. P. Mahon Acellular Pertussis Vaccine Protects against Exacerbation of Allergic Asthma Due to Bordetella pertussis in a Murine Model Clin. Vaccine Immunol., March 1, 2005; 12(3): 409 - 417. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Wittke, V. Weaver, B. D. Mahon, A. August, and M. T. Cantorna Vitamin D Receptor-Deficient Mice Fail to Develop Experimental Allergic Asthma J. Immunol., September 1, 2004; 173(5): 3432 - 3436. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Kudlacz, C. J. Andresen, M. Salafia, C. A. Whitney, B. Naclerio, and P. S. Changelian Genetic Ablation of the src Kinase p59fynT Exacerbates Pulmonary Inflammation in an Allergic Mouse Model Am. J. Respir. Cell Mol. Biol., April 1, 2001; 24(4): 469 - 474. [Abstract] [Full Text] |
||||
![]() |
E. Hamelmann, K. Takeda, A. Haczku, G. Cieslewicz, L. Shultz, Q. Hamid, Z. Xing, J. Gauldie, and E. W. Gelfand Interleukin (IL)-5 but Not Immunoglobulin E Reconstitutes Airway Inflammation and Airway Hyperresponsiveness in IL-4-Deficient Mice Am. J. Respir. Cell Mol. Biol., September 1, 2000; 23(3): 327 - 334. [Abstract] [Full Text] |
||||
![]() |
A. HACZKU, K. TAKEDA, E. HAMELMANN, J. LOADER, A. JOETHAM, I. REDAI, C. G. IRVIN, J. J. LEE, H. KIKUTANI, D. CONRAD, et al. CD23 Exhibits Negative Regulatory Effects on Allergic Sensitization and Airway Hyperresponsiveness Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): 952 - 960. [Abstract] [Full Text] [PDF] |
||||